^
    Back
    Association details:
    Biomarker:ALK I1171
    Cancer:Non Small Cell Lung Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    J Thorac Oncol
    Title:

    Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib

    Excerpt:
    In addition to the novel finding of mutations at I1171 in ALK-rearranged patients, it is intriguing that mutations at I1171 confer resistance to both crizotinib and alectinib, which is a representative second-generation ALK inhibitor.
    DOI:
    10.1097/JTO.0000000000000358